CYTOCHROME P450 AND LUNG IN HUMAN PRETERM INFANTS

描述(改编自调查者摘要)：本报告的目标 项目是确定肺细胞色素P-450在介导肺损伤中的作用 在有BPD风险的早产儿中。目标1是确定是否 细胞色素P-450抑制剂西咪替丁将减少早期肺损伤，因为 反映在肺气体交换，在人类早产儿有风险 每桶。目的2是确定研究中的脂质过氧化程度 通过测定患者气管和支气管液中的F2-异前列腺素水平 尿液中也有。目的3鉴定P-450介导的花生四烯酸(AA) 从登记的患者中获得的气管和支气管液中的代谢物 研究并将特定代谢物的水平与 分配处理和气体交换指标。目标4是确定 气管、支气管液和尿液中炎性标志物的检测 对患者进行研究，以确定氧气的预期减少 患者体内自由基生成和P-450AA代谢产物的产生 接受西咪替丁治疗还伴随着炎症反应的减少。

DESCRIPTION (Adapted from the Investigator's Abstract): The goal of this project is to determine the role of lung cyt P-450 in mediating lung injury in the newborn premature infant at risk for BPD. Aim 1 is to determine if the cyt P-450 inhibitor cimetidine will reduce early lung injury, as reflected by pulmonary gas exchange, in human premature infants at risk for BPD. Aim 2 is to determine the degree of lipid peroxidation in study patients by measuring F2-isoprostane levels in tracheobronchial aspirates and in urine. Aim 3 is to identify P-450 mediated arachidonic acid (AA) metabolites in tracheobronchial aspirates obtained from patients enrolled in the study and to correlate the levels of specific metabolites with the assigned treatment and gas exchange index. Aim 4 is to identify inflammatory markers in tracheobronchial aspirates and urine obtained from study patients in order to determine whether the anticipated reduction in O2 free radical generation and P-450 AA metabolite production in patients receiving cimetidine is also accompanied by a reduced inflammatory response.